Status:

COMPLETED

The ARIES HeartMate 3 Pump IDE Study

Lead Sponsor:

Abbott Medical Devices

Conditions:

Heart Failure

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Prospective, randomized, double-blinded, placebo-controlled clinical investigation of advanced heart failure patients treated with the HM3 with two different antithrombotic regimens: vitamin K antagon...

Detailed Description

This clinical investigation is a prospective, randomized, double-blinded, placebo-controlled study of advanced heart failure patients treated with the HM3 with two different antithrombotic regimens: v...

Eligibility Criteria

Inclusion

  • Subject will receive the HeartMate 3 per standard of care (SOC) in accordance with the approved indications for use in the country of implant.
  • Subject will receive the HeartMate 3 as their first durable VAD.
  • Subject must provide written informed consent prior to any clinical investigation related procedure.
  • In female patients of child bearing capability, subject will not be currently pregnant or breastfeeding and on appropriate contraception.

Exclusion

  • Post-implant additional temporary or permanent mechanical circulatory support (MCS).
  • Investigator mandated antiplatelet therapy for other conditions (including mandated presence or absence of antiplatelet agent).
  • Patients who are nil per os (NPO) post-implant through day 7.
  • Subjects with a known allergy to acetylsalicylic acid (aspirin).
  • Participation in any other clinical investigation(s) involving an MCS device, or interventional investigation(s) likely to confound study results or affect study outcome.
  • Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results.

Key Trial Info

Start Date :

July 14 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 10 2023

Estimated Enrollment :

628 Patients enrolled

Trial Details

Trial ID

NCT04069156

Start Date

July 14 2020

End Date

August 10 2023

Last Update

March 27 2025

Active Locations (51)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 13 (51 locations)

1

Baptist Health Medical Center

Little Rock, Arkansas, United States, 72205

2

University of California, San Diego

La Jolla, California, United States, 92037

3

Stanford University Medical Center

Palo Alto, California, United States, 94304

4

Sharp Memorial Hospital

San Diego, California, United States, 92123